Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H27N5O2 |
Molecular Weight | 417.5035 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCOC1=CC=C2N(C=NC2=C1)C3=NC4=C(C=CC=C4C=C3)N5CCC(N)CC5
InChI
InChIKey=DEEOXSOLTLIWMG-UHFFFAOYSA-N
InChI=1S/C24H27N5O2/c1-30-13-14-31-19-6-7-21-20(15-19)26-16-29(21)23-8-5-17-3-2-4-22(24(17)27-23)28-11-9-18(25)10-12-28/h2-8,15-16,18H,9-14,25H2,1H3
Molecular Formula | C24H27N5O2 |
Molecular Weight | 417.5035 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15705896
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15705896
CP-673,451 is a potent inhibitor of platelet-derived growth factor beta-receptor (PDGFR-beta) kinase- and PDGF-BB-stimulated autophosphorylation of PDGFR-beta in cells. CP 673451 in a sponge implant model where a surgical sponge was soaked with PDGFBB to initiate angiogenesis, CP 673451 inhibited 75% of PDGF-BB-stimulated angiogenesis at a dose of 3 mg/kg for 5 days. CP 673451 did not inhibit angiogenesis induced by either VEGF or bFGF in the sponge. CP 673451 also inhibited tumour growth in H460 human lung carcinoma, Colo205 and LS174T human colon carcinomas and U87MG human glioblastoma multiforme xenograft models. CP-673,451 has not been studied in clinical trials due to issues with toxicity in preclinical studies.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1913 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15705896 |
1.0 nM [IC50] | ||
Target ID: CHEMBL2007 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15705896 |
10.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15705896
Athymic female mice (CD-1 nu/nu, ~20 grams) were used for In vivo evaluation of antiangiogenesis. Animals received CP-673451 doses of 3, 10, or 33 mg/kg q.d. p.o. for 5 days. PDGF-BB-induced angiogenesis was inhibited by 70-90% following 5 daily oral doses of 3-30 mg/kg CP-673,451.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15705896
Porcine aortic endothelial (PAE) cells stably expressing full-length PDGFR was used for Cell-Based Phospho-PDGFR Inhibition Assay. CP-673451 was diluted in 100% DMSO, added to the cells at a final DMSO concentration of 0.25% v/v, and incubated at 370C for 10 minutes. CP-673451 (1-100nM) shows potent inhibition of PDGFR-beta phosphorylation.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:18:38 GMT 2023
by
admin
on
Sat Dec 16 08:18:38 GMT 2023
|
Record UNII |
0AM0WWD90A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
343787-29-1
Created by
admin on Sat Dec 16 08:18:38 GMT 2023 , Edited by admin on Sat Dec 16 08:18:38 GMT 2023
|
PRIMARY | |||
|
10158940
Created by
admin on Sat Dec 16 08:18:38 GMT 2023 , Edited by admin on Sat Dec 16 08:18:38 GMT 2023
|
PRIMARY | |||
|
DTXSID20187948
Created by
admin on Sat Dec 16 08:18:38 GMT 2023 , Edited by admin on Sat Dec 16 08:18:38 GMT 2023
|
PRIMARY | |||
|
804551-39-1
Created by
admin on Sat Dec 16 08:18:38 GMT 2023 , Edited by admin on Sat Dec 16 08:18:38 GMT 2023
|
SUPERSEDED | |||
|
0AM0WWD90A
Created by
admin on Sat Dec 16 08:18:38 GMT 2023 , Edited by admin on Sat Dec 16 08:18:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |